Pembrolizumab
GastroEsophageal Cancer
Diwakar Davarmonoclonal_antibodyPhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 81/ 100
Competitive context
46 Active assets in the GastroEsophageal Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin Incyte Corporation | Phase 1/2 | B |
FLUOROURACILUM Incyte Corporation | Phase 1/2 | B |
Carboplatin Iambic Therapeutics, Inc | Phase 1/2 | B |
Cyclophosphamide Diwakar Davar | Phase 2 | B |
Docetaxel Oscotec Inc. | Phase 2 | B |
View all 50 →
Same molecule, other indications
Pembrolizumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →